건강보험자료를 이용한 12세 미만 소아에서 코데인 처방양상평가
Prescribing Patterns of Codeine among Children under Aged 12 in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Codeine may result in death or respiratory depression in children, particularly who are rapid metabolizer of CYP2D6, therefore it should be used cautiously among children under 12 years of age. This study was to investigate the prescribing pattern of codeine among children according to the age group, prescribed diagnosis, type of medical service and medical specialties. Method: We used Korea Health Insurance Review and Assessment Service-National Patient Sample (HIRA-NPS) database. Study subjects included inpatients or outpatients, who were prescribed codeine between January, 1, 2011 and December, 31, 2011. Contraindicated use of codeine was defined as the use of codeine at least one times under aged 12. Age groups were subclassified according to the <2 years, 2-4 years, 5-8 years, and 9-11 years. Frequently prescribed diagnosis (ICD-10), type of medical service, and medical specialties were also described among codeine users under aged 12. Results: Codeine users were 6,411 inpatients (9,958 prescriptions), and 3,397 outpatients (6,258 prescriptions), respectively. Codeine prescription under 12 years of age were 2.1% (210 prescriptions) among inpatients, and 12.3% (776 prescriptions) among outpatients (p-value<0.05). Outpatient prescriptions of codeine under 12 aged were issued mostly from primary care clinics and frequent diagnosis were unspecified bronchopneumonia (51.6%), and vasomotor rhinitis (23.7%). Conclusion: This study found prescribing of codeine under 12 aged is common in outpatient and primary clinics. Nationwide and community-based efforts should be needed to reduce inappropriate prescribing among children.
Abstract
Objective: Codeine may result in death or respiratory depression in children, particularly who are rapid metabolizer of CYP2D6, therefore it should be used cautiously among children under 12 years of age. This study was to investigate the prescribing pattern of codeine among children according to the age group, prescribed diagnosis, type of medical service and medical specialties. Method: We used Korea Health Insurance Review and Assessment Service-National Patient Sample (HIRA-NPS) database. Study subjects included inpatients or outpatients, who were prescribed codeine between January, 1, 2011 and December, 31, 2011. Contraindicated use of codeine was defined as the use of codeine at least one times under aged 12. Age groups were subclassified according to the <2 years, 2-4 years, 5-8 years, and 9-11 years. Frequently prescribed diagnosis (ICD-10), type of medical service, and medical specialties were also described among codeine users under aged 12. Results: Codeine users were 6,411 inpatients (9,958 prescriptions), and 3,397 outpatients (6,258 prescriptions), respectively. Codeine prescription under 12 years of age were 2.1% (210 prescriptions) among inpatients, and 12.3% (776 prescriptions) among outpatients (p-value<0.05). Outpatient prescriptions of codeine under 12 aged were issued mostly from primary care clinics and frequent diagnosis were unspecified bronchopneumonia (51.6%), and vasomotor rhinitis (23.7%). Conclusion: This study found prescribing of codeine under 12 aged is common in outpatient and primary clinics. Nationwide and community-based efforts should be needed to reduce inappropriate prescribing among children.
참고문헌 (29)
- Madadi P., "Pharmacogenetic insights into codeine analgesia : implications to pediatric codeine use", Pharmacogenomics, 9(9), pp.1267~1284 (2008)
- D. G. Williams., "Codeine phosphate in paediatric medicine", Br J Anaesth, 86(3), pp.413~421 (2001)
- Takahama K., "Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs", Cough, 3, pp.8~ (2007)[DOI]
- World Health Organization, "Cancer Pain Relief and Palliative Care in Children Geneva" (1998), World Health Organization
- Tremlett M., "Pro-con debate : is codeine a drug that still has a useful role in pediatric practice?", Paediatr Anaesth, 20(2), pp.183~194 (2010)
- de Lima J., "Infant and neonatal pain : anaesthetists' perceptions and prescribing patterns", BMJ, 313(7060), pp.787~ (1996)
- Neubert A., "The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands", Pharmacol Res, 62(3), pp.243~248 (2010)
- Matthys H Fau-Bleicher B., "Dextromethorphan and codeine : objective assessment of antitussive activity in patients with chronic cough", J Int Med Res, 11(2), pp.92~100 (1983)
- Ciszkowski C., "Codeine, ultrarapid-metabolism genotype, and postoperative death", N Engl J Med, 361(8), pp.827~828 (2009)
- Kelly LE., "More codeine fatalities after tonsillectomy in North American children", Pediatrics, 129(5), pp.1343~1347 (2012)
- "WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses 2012" (2012)[URL]
- "Restrictions on use of codeine for pain relief in children - CMDh endorses PRAC recommendation"[URL]
- "Codeine for analgesia: restricted use in children because of reports of morphine toxicity"[URL]
- "Health Canada’s review recommends codeine only be used in patients aged 12 and over 2013"[URL]
- Kim LG., "A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples", Epidemiol Health, 36, pp.e2014008~ (2014)[DOI]
- American Academy of Pediatrics., "Use of codeine- and dextromethorphan-containing cough remedies in children. American Academy of Pediatrics. Committee on Drugs", Pediatrics, 99(6), pp.918~920 (1997)
- Friedrichsdorf SJ., "Codeine-associated pediatric deaths despite using recommended dosing guidelines : three case reports", J Opioid Manag, 9(2), pp.151~155 (2013)
- "Geneva: World Health Organization. WHO Guidelines on the Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses", WHO Guidelines Approved by the Guidelines Review Committee, ~ (2012)
- Kaiser SV., "National patterns of codeine prescriptions for children in the emergency department", Pediatrics, 133(5), pp.1139~1147 (2014)
- Lasky T., "Estimating pediatric inpatient medication use in the United States", Pharmacoepidemiol Drug Saf, 20(1), pp.76~82 (2011)
- World Health Organization, "Dept. of Child and Adolescent Health and Development. Cough and cold remedies for the treatment of acute respiratory in young children", ~ (2001)
- J C de Jongste., "Cough°§2 : Chronic cough in children", Thorax, 58, pp.998~1003 (2003)
- Bolser DC., "Codeine and cough : an ineffective gold standard", Curr Opin Allergy Clin Immunol, 7(1), pp.32~36 (2007)
- Goldman RD, "Codeine for acute cough in children", Can Fam Physician, 56(12), pp.1293~1294 (2010)
- Kelley LK., "Managing acute cough in children : evidencebased guidelines", Pediatr Nurs, 33(6), pp.515~524 (2007)
- R Jhaj VB., "Use of cold medications for upper respiratory tract infections in children", Pharmacoepidemiol Drug Saf, 10, pp.323~327 (2001)
- Chang CC., "Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults", Cochrane Database Syst Rev, 3 (2014)[DOI]
- Sen EF., "Effects of safety warnings on prescription rates of cough and cold medicines in children below 2years of age", Br J Clin Pharmacol, 71(6), pp.943~950 (2011)
- Chang AB., "Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines", Chest, 129(1 Suppl), pp.260S~283S (2006)